Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Arcus Biosciences Is Losing Ground Today

By Cory Renauer – May 27, 2020 at 3:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.

What happened

Shares of Arcus Biosciences (RCUS -4.74%), a clinical-stage biotechnology company developing novel cancer therapies, are getting beaten down following an announcement that should be highly positive. Instead of a juicy buyout offer, Gilead Sciences (GILD -1.34%) has decided to forge a collaboration agreement. As a result, the stock has fallen 19.44% as of 3:55 p.m. EDT on Wednesday.

So what 

Back in April, shares of Arcus soared after an article in Bloomberg suggested Gilead Sciences would acquire a large stake, or perhaps all of Arcus Biosciences. Instead, Arcus will receive $175 up front and a $200 equity investment as part of a partnership to co-develop potential new cancer therapies.

Coins falling through someone's hands.

Image source: Getty Images.

Despite its relatively small size, Arcus' pipeline already boasts four novel cancer therapy candidates in 10 separate clinical trials. This flurry of clinical activity boosts the chances of success, but it also comes at a price. Arcus finished March with $158 million in cash after losing $27.5 million in the first quarter.

Now what

In addition to $375 million in upfront consideration, Arcus is eligible to receive up to $1.2 billion in the form of opt-in and milestone payments. Gilead Sciences gains access to the company's current and future cancer drugs with immediate rights to zimberelimab, an experimental anti-PD1 drug that works along the same lines as Keytruda from Merck (MRK -0.16%).

Further down the road, Gilead Sciences has the right to opt into all other current Argus clinical candidates for a fee that ranges between $200 million and $275 million per program. Gilead also retains the right to opt in to all other programs that emerge from the Arcus research portfolio over the next 10 years for the relatively low price of $150 million each.

In the U.S., the partners will co-commercialize any cancer therapies that earn FDA approval. Gilead will handle international sales and give Arcus a tiered royalty percentage that tops out in the low 20s.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arcus Biosciences, Inc. Stock Quote
Arcus Biosciences, Inc.
$25.53 (-4.74%) $-1.27
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$86.64 (-0.16%) $0.14
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.07 (-1.34%) $0.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.